PL3923971T3 - Analizowanie wpływu polirybonukleotydu na ciliogenezę - Google Patents

Analizowanie wpływu polirybonukleotydu na ciliogenezę

Info

Publication number
PL3923971T3
PL3923971T3 PL20704031.2T PL20704031T PL3923971T3 PL 3923971 T3 PL3923971 T3 PL 3923971T3 PL 20704031 T PL20704031 T PL 20704031T PL 3923971 T3 PL3923971 T3 PL 3923971T3
Authority
PL
Poland
Prior art keywords
ciliogenesis
polyribonucleotide
analyzing
effect
Prior art date
Application number
PL20704031.2T
Other languages
English (en)
Inventor
Carsten Rudolph
Verena Mummert
Rebekka Kubisch-Dohmen
Christian Dohmen
Johannes Geiger
Manish ANEJA
Ludwig Weiss
Heymut OMRAN
Petra PENNEKAMP
Kai WOHLGEMUTH
Sandra CINDRIC
Niki Tomas LOGES
Johanna RAIDT
Adrian TER STEEGE
Original Assignee
Ethris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethris Gmbh filed Critical Ethris Gmbh
Publication of PL3923971T3 publication Critical patent/PL3923971T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
PL20704031.2T 2019-02-14 2020-02-13 Analizowanie wpływu polirybonukleotydu na ciliogenezę PL3923971T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157210 2019-02-14
PCT/EP2020/053774 WO2020165352A1 (en) 2019-02-14 2020-02-13 Treatment of ciliopathies

Publications (1)

Publication Number Publication Date
PL3923971T3 true PL3923971T3 (pl) 2024-03-25

Family

ID=65440876

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20704031.2T PL3923971T3 (pl) 2019-02-14 2020-02-13 Analizowanie wpływu polirybonukleotydu na ciliogenezę

Country Status (14)

Country Link
US (1) US20220211807A1 (pl)
EP (2) EP3923971B1 (pl)
JP (2) JP2022522412A (pl)
KR (1) KR20210127718A (pl)
CN (1) CN113423418A (pl)
AU (1) AU2020220636A1 (pl)
BR (1) BR112021014528A2 (pl)
CA (2) CA3225057A1 (pl)
ES (1) ES2974368T3 (pl)
HU (1) HUE065017T2 (pl)
MX (1) MX2021009388A (pl)
PL (1) PL3923971T3 (pl)
WO (1) WO2020165352A1 (pl)
ZA (1) ZA202106769B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109562192B (zh) 2016-05-27 2023-08-15 创思瑞普泰克斯公司 用合成信使rna治疗原发性纤毛运动障碍
US20240123087A1 (en) * 2021-03-19 2024-04-18 Recode Therapeutics, Inc. Polynucleotide compositions, related formulations, and methods of use thereof
WO2022204053A1 (en) * 2021-03-22 2022-09-29 Recode Therapeutics, Inc. Polynucleotide compositions, related formulations, and methods of use thereof
WO2023014887A1 (en) * 2021-08-04 2023-02-09 The Trustees Of Indiana University Methods of treating compromised lung function and assessing clinical improvement

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
ATE208369T1 (de) 1997-08-13 2001-11-15 Biontex Lab Gmbh Neue lipopolyamine, deren darstellung und anwendung
WO2001000708A1 (de) 1999-06-25 2001-01-04 Christian Plank Kombinationen zur einführung von nucleinsäuren in zellen
ATE536418T1 (de) 2004-06-07 2011-12-15 Protiva Biotherapeutics Inc Lipidverkapselte interferenz-rna
FR2925491B1 (fr) 2007-12-19 2010-09-03 Oz Biosciences Sas Nouvelle classe de lipides cationiques pour le transport d'agents actifs dans les cellules
JP6561378B2 (ja) * 2012-06-08 2019-08-21 トランスレイト バイオ, インコーポレイテッド 非肺標的細胞へのmRNAの経肺送達
KR20150020288A (ko) * 2012-06-08 2015-02-25 에트리스 게엠베하 메신저 rna의 폐전달
WO2014020723A1 (ja) 2012-08-01 2014-02-06 株式会社コナミデジタルエンタテインメント 処理装置、処理装置の制御方法、及び、処理装置のプログラム
EA036400B1 (ru) * 2013-06-28 2020-11-06 Этрис Гмбх Композиции для введения рнк в клетки
CN107405412A (zh) * 2014-11-10 2017-11-28 埃泽瑞斯公司 通过递送bmp编码rna诱导骨生成
CN109562192B (zh) * 2016-05-27 2023-08-15 创思瑞普泰克斯公司 用合成信使rna治疗原发性纤毛运动障碍
GB201707212D0 (en) * 2017-05-05 2017-06-21 Ucl Business Plc Gene therapy for ciliopathies

Also Published As

Publication number Publication date
MX2021009388A (es) 2021-09-10
CA3225057A1 (en) 2020-08-20
CA3129912A1 (en) 2020-08-20
EP3923971C0 (en) 2023-12-20
BR112021014528A2 (pt) 2021-10-13
EP4223306A3 (en) 2023-11-29
EP4223306A2 (en) 2023-08-09
ES2974368T3 (es) 2024-06-27
EP3923971A1 (en) 2021-12-22
JP2022522412A (ja) 2022-04-19
JP2024096766A (ja) 2024-07-17
WO2020165352A1 (en) 2020-08-20
ZA202106769B (en) 2024-01-31
AU2020220636A1 (en) 2021-07-29
US20220211807A1 (en) 2022-07-07
HUE065017T2 (hu) 2024-04-28
EP3923971B1 (en) 2023-12-20
KR20210127718A (ko) 2021-10-22
CN113423418A (zh) 2021-09-21

Similar Documents

Publication Publication Date Title
CA191264S (en) Analyzing instrument
SG11202106762UA (en) Analysing a body
GB201903347D0 (en) Execution unit
EP3923971C0 (en) ANALYSIS OF THE EFFECT OF A POLYRIBONUCLEOTIDE ON CILIOGENesis
CA189989S (en) Cuvette
GB201903346D0 (en) Execution unit
GB201903827D0 (en) New compounds and methods
GB2582143B (en) Execution unit
GB201903832D0 (en) New compounds and methods
GB201903348D0 (en) Execution unit
GB201902077D0 (en) Biomarkers
GB2570742B (en) Optical-interference analysis
GB201908045D0 (en) Object analysis
CA189106S (en) Fastener
SG11202113179WA (en) Context detection
GB201900677D0 (en) Biomarkers
GB201913110D0 (en) New compounds and methods
GB201913035D0 (en) Test
GB2580670B (en) Monitoring
GB2583714B (en) Non-Invasive Measurement
GB201903430D0 (en) Assembly and device therefor
GB2585410B (en) Analysis
GB2596002B (en) Object analysis
GB2587622B (en) Small fastener
GB201915837D0 (en) Probe